Cleared Traditional

K232991 - BT-1000

K232991 is an FDA 510(k) clearance for BT-1000, manufactured by Bistos Co., Ltd.. The device is a Class 2 Neurology device with product code QGL cleared through the Traditional 510(k) pathway after a 341-day FDA review.

K232991 · Bistos Co., Ltd. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2024
Decision
341d
Days
Class 2
Risk

K232991 is an FDA 510(k) clearance for the BT-1000. Classified as Transcutaneous Nerve Stimulator For Adhd (product code QGL), Class II - Special Controls.

Submitted by Bistos Co., Ltd. (Gyeonggi, KR). The FDA issued a Cleared decision on August 28, 2024 after a review of 341 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5898 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.

View all Bistos Co., Ltd. devices

FDA 510(k) Submission Details - K232991

510(k) Number K232991 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 22, 2023
Decision Date August 28, 2024
Days to Decision 341 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
193d slower than avg
Panel avg: 148d · This submission: 341d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

QGL Device Classification - Class 2, Special Controls

Product Code QGL Transcutaneous Nerve Stimulator For Adhd
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5898
Definition A Transcutaneous Electrical Nerve Stimulator For Attention Deficit Hyperactivity Disorder (adhd) Is A Prescription Device That Stimulates Transcutaneously Or Percutaneously Through Electrodes Placed On The Forehead.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.